FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - October 10, 2025 72 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Fructose Fuels Cancer Growth Indirectly, Lab Study Finds January 14, 2025 Teclistamab Results in a High Rate of Deep and Durable Response... August 22, 2022 News digest – cancer blood test, gum disease and junk food... July 25, 2020 FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic... August 3, 2020 Load more HOT NEWS Group of Breast Cancer Survivors is Finding New Strength from Fitness... FDA Approves Nivolumab in Combination with Chemotherapy and Nivolumab in Combination... Professor Eithne Costello: On the road to early detection Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and...
